Overview
Investment Type
Venture Capital
Mentions in press and media 5
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 6, 2016 | How fabled research lab SRI invents the future, one startup at a time | Nick Triantos was on a mission to find a job where he could help build the next big thing. This ultimately drew him to SRI, where he currently serves as managing director of the nonprofit research firm’s venture arm. SRI has a storied past ... |
| Apr 15, 2009 | Cancer drug maker BiPar sells to Sanofi-aventis for $500M | BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divid... |
| Jan 13, 2009 | BiPar snags $20M for inhibitor-based cancer therapies | Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based co... |
| May 11, 2007 | StrataGent closes $16M round for needle-free injections | StrataGent Life Sciences, a San Jose developer of needle-free “microjet” injection systems, said it closed a $16 million second round of financing. The company has so far received $6.65 million of that round; the remainder should become ava... |
Reviews 0
FAQ about Quantum Technology Partners
What has the press written about Quantum Technology Partners?
Parsers VC has collected 5 articles mentioning Quantum Technology Partners, among them “How fabled research lab SRI invents the future, one startup at a time” (Mar 6, 2016) and “Cancer drug maker BiPar sells to Sanofi-aventis for $500M” (Apr 15, 2009).
Is Quantum Technology Partners still active?
Yes, Quantum Technology Partners is active; its latest activity on Parsers VC dates from Mar 6, 2016.